Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Target Price at $4.93

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have earned a consensus rating of “Hold” from the seven analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $4.93.

A number of equities analysts have issued reports on SGMO shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a report on Thursday, March 14th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective (up previously from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday, March 19th. Finally, StockNews.com assumed coverage on shares of Sangamo Therapeutics in a research report on Tuesday, February 13th. They set a “sell” rating on the stock.

Sangamo Therapeutics Trading Up 2.0 %

Shares of Sangamo Therapeutics stock opened at $0.50 on Tuesday. The firm’s 50 day moving average is $0.80 and its 200 day moving average is $0.59. The firm has a market capitalization of $104.37 million, a PE ratio of -0.34 and a beta of 1.39. Sangamo Therapeutics has a 1 year low of $0.29 and a 1 year high of $1.78.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.09). The company had revenue of $2.04 million for the quarter, compared to the consensus estimate of $8.96 million. Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. As a group, research analysts anticipate that Sangamo Therapeutics will post -0.54 earnings per share for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of institutional investors have recently modified their holdings of the company. Miracle Mile Advisors LLC acquired a new position in shares of Sangamo Therapeutics in the 3rd quarter valued at about $25,000. Vanguard Personalized Indexing Management LLC acquired a new position in Sangamo Therapeutics in the third quarter valued at approximately $26,000. Mackenzie Financial Corp boosted its holdings in shares of Sangamo Therapeutics by 72.4% during the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 31,003 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Sangamo Therapeutics by 255.2% during the 3rd quarter. SG Americas Securities LLC now owns 88,542 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 63,612 shares during the period. Finally, Golden State Equity Partners grew its position in shares of Sangamo Therapeutics by 22.5% during the 3rd quarter. Golden State Equity Partners now owns 166,265 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 30,500 shares during the period. 56.93% of the stock is owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.